Weight-loss wonder drugs get FDA warning label for "rare eye disease"; Novo Nordisk (NVO.US), Eli Lilly (LLY.US): no evidence of causation

Zhitong Finance APP has learned that the U.S. Food and Drug Administration (FDA) said on Monday that after finding evidence of a potentially increased risk of a rare eye disease, it will require all GLP-1 drugs to add a new safety warning.